Literature DB >> 28361221

Eighth edition of AJCC staging for differentiated thyroid cancer: Is stage I appropriate for T4/N1b patients aged 45-55 years?

Pedro Weslley Rosario1.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28361221     DOI： 10.1007/s12020-017-1288-3

Source DB:  PubMed          Journal:  Endocrine        ISSN： 1355-008X            Impact factor:   3.633


× No keyword cloud information.
  5 in total

1.  An International Multi-Institutional Validation of Age 55 Years as a Cutoff for Risk Stratification in the AJCC/UICC Staging System for Well-Differentiated Thyroid Cancer.

Authors:  Iain J Nixon; Laura Y Wang; Jocelyn C Migliacci; Antoine Eskander; Michael J Campbell; Ahmad Aniss; Lilah Morris; Fernanda Vaisman; Rossana Corbo; Denise Momesso; Mario Vaisman; Andre Carvalho; Diana Learoyd; William D Leslie; Richard W Nason; Deborah Kuk; Volkert Wreesmann; Luc Morris; Frank L Palmer; Ian Ganly; Snehal G Patel; Bhuvanesh Singh; R Michael Tuttle; Ashok R Shaha; Mithat Gönen; K Alok Pathak; Wen T Shen; Mark Sywak; Luis Kowalski; Jeremy Freeman; Nancy Perrier; Jatin P Shah
Journal:  Thyroid       Date:  2016-02-25       Impact factor: 6.568

2.  Increasing incidence of thyroid cancer in the United States, 1973-2002.

Authors:  Louise Davies; H Gilbert Welch
Journal:  JAMA       Date:  2006-05-10       Impact factor: 56.272

3.  No significant difference in the prognostic value of the 5th and 7th editions of AJCC staging for differentiated thyroid cancer.

Authors:  Alexis Vrachimis; Joachim Gerss; Maren Stoyke; Christian Wittekind; Tobias Maier; Christian Wenning; Kambiz Rahbar; Otmar Schober; Burkhard Riemann
Journal:  Clin Endocrinol (Oxf)       Date:  2014-02-04       Impact factor: 3.478

4.  The TNM system (version 7) is the most accurate staging system for the prediction of loss of life expectancy in differentiated thyroid cancer.

Authors:  Karina Tanase; Elena-Daphne Thies; Uwe Mäder; Christoph Reiners; Frederik A Verburg
Journal:  Clin Endocrinol (Oxf)       Date:  2015-03-30       Impact factor: 3.478

5.  Exploring the Relationship Between Patient Age and Cancer-Specific Survival in Papillary Thyroid Cancer: Rethinking Current Staging Systems.

Authors:  Mohamed Abdelgadir Adam; Samantha Thomas; Terry Hyslop; Randall P Scheri; Sanziana A Roman; Julie A Sosa
Journal:  J Clin Oncol       Date:  2016-10-28       Impact factor: 44.544
  5 in total
  5 in total

1.  Risk Stratification in Differentiated Thyroid Cancer: From Detection to Final Follow-up.

Authors:  R Michael Tuttle; Ali S Alzahrani
Journal:  J Clin Endocrinol Metab       Date:  2019-03-15       Impact factor: 5.958

2.  Using the American Thyroid Association Risk-Stratification System to Refine and Individualize the American Joint Committee on Cancer Eighth Edition Disease-Specific Survival Estimates in Differentiated Thyroid Cancer.

Authors:  Sana A Ghaznavi; Ian Ganly; Ashok R Shaha; Crystal English; Jonathan Wills; R Michael Tuttle
Journal:  Thyroid       Date:  2018-08-02       Impact factor: 6.568

3.  Patients Aged ≥55 Years With Stage T1-2N1M1 Differentiated Thyroid Cancer Should Be Downstaged in the Eighth Edition AJCC/TNM Cancer Staging System.

Authors:  Zeming Liu; Sichao Chen; Yihui Huang; Di Hu; Min Wang; Wei Wei; Chao Zhang; Wen Zeng; Liang Guo
Journal:  Front Oncol       Date:  2019-10-18       Impact factor: 6.244

4.  Impact of the 8th Edition of the AJCC-TNM Staging System on Estimated Cancer-Specific Survival in Patients Aged 45-54 Years at Diagnosis with Differentiated Thyroid Carcinoma: A Single Center Report.

Authors:  Riccardo Maggiore; Francesca Perticone; Gilberto Mari; Riccardo Pasquali; Emanuele Bosi; Marina Scavini; Roberto Lanzi; Riccardo Rosati
Journal:  Int J Endocrinol       Date:  2021-02-22       Impact factor: 3.257

5.  Using The Cancer Genome Atlas data to refine the 8th edition of the American Joint Committee on Cancer staging for papillary thyroid carcinoma.

Authors:  Anello Marcello Poma; Elisabetta Macerola; Liborio Torregrossa; Rossella Elisei; Ferruccio Santini; Fulvio Basolo
Journal:  Endocrine       Date:  2020-09-11       Impact factor: 3.633
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.